J&J Highlights FDA Approval of STELARA® for Pediatric Crohn’s Disease
The U.S. Food and Drug Administration (FDA) has approved STELARA (ustekinumab) for the treatment of pediatric patients aged two years and older with moderately to severely active Crohn’s disease (CD). This decision marks a significant advancement in the management of pediatric inflammatory bowel disease, particularly for younger patients who have historically had limited treatment options.
Expanding Treatment Options for Young Patients
With this approval, STELARA becomes the first non–tumor necrosis factor (non-TNF) biologic therapy available for children as young as two years old with moderate-to-severe Crohn’s disease. It is also the only FDA-approved therapy that works by selectively inhibiting interleukin-12 (IL-12) and interleukin-23 (IL-23), two key cytokines involved in immune system signaling and inflammation.
Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract that can lead to symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. In the United States alone, nearly one million people are living with the disease, and up to 25% of cases are diagnosed during childhood or adolescence. Pediatric Crohn’s disease is often more aggressive than adult-onset disease, with a higher likelihood of complications such as growth delays, malnutrition, and long-term intestinal damage.
The availability of STELARA for this younger population provides clinicians with a new mechanism of action to target the disease, especially for patients who may not respond adequately to traditional therapies or TNF inhibitors.
Clinical Evidence Supporting Approval
The FDA’s decision was supported by results from the Phase 3 UNITI-Jr clinical trial, a multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of ustekinumab in pediatric patients with Crohn’s disease. The study followed patients over a 52-week period, consisting of an 8-week induction phase and a 44-week maintenance phase.
The trial demonstrated that STELARA was effective in reducing disease activity and maintaining clinical response in children with moderate-to-severe Crohn’s disease. Importantly, the safety profile observed in pediatric patients was consistent with what has been previously reported in adult clinical trials, reinforcing confidence in the therapy’s use across age groups.
Safety and Tolerability Profile
As with any biologic therapy that modulates the immune system, STELARA carries certain safety considerations. In the pediatric population studied in the UNITI-Jr trial, the most commonly reported adverse events during the induction phase included upper respiratory tract infections, affecting approximately 13% of patients.
During the maintenance phase, common adverse reactions included upper respiratory tract infections (17%), COVID-19 infections (17%), and headaches (10%). These findings align with the known safety profile of ustekinumab in adult patients, where infections are among the most frequently observed side effects.
Because STELARA works by suppressing specific components of the immune system, it may increase the risk of serious infections. Other potential risks include the development of certain types of cancer, serious allergic reactions, lung inflammation, and rare neurological conditions such as posterior reversible encephalopathy syndrome (PRES).
Healthcare providers are advised to carefully evaluate each patient’s medical history before initiating treatment and to monitor for signs of infection or other adverse events במהלך therapy.
Mechanism of Action: A Targeted Approach
STELARA’s mechanism of action distinguishes it from other biologic therapies used in Crohn’s disease. By targeting IL-12 and IL-23, the drug interrupts key inflammatory pathways that drive the disease process. This dual inhibition helps reduce immune-mediated inflammation in the gastrointestinal tract, leading to symptom relief and improved clinical outcomes.
Unlike TNF inhibitors, which broadly suppress inflammation, STELARA offers a more targeted approach. This can be particularly beneficial for patients who have not responded to or cannot tolerate TNF-based therapies, providing an alternative pathway for disease control.
Addressing an Unmet Need in Pediatric Care
The approval of STELARA for children as young as two years old addresses a longstanding gap in pediatric gastroenterology. Historically, treatment options for young patients with Crohn’s disease have been limited, often relying on medications developed primarily for adults.
This gap is especially concerning given the unique challenges of managing Crohn’s disease in children. The disease can interfere with normal growth and development, affect nutritional status, and impose a significant burden on quality of life during critical formative years.
By expanding access to advanced biologic therapies like STELARA, clinicians now have more tools to tailor treatment strategies to the needs of pediatric patients, potentially improving long-term outcomes and reducing the risk of complications.
Important Safety Considerations
STELARA is a prescription medication that affects the immune system and is not appropriate for all patients. Only a qualified healthcare provider can determine whether it is suitable for an individual patient.
Patients and caregivers should be aware of the potential risks associated with treatment, including serious infections, malignancies, allergic reactions, and other immune-related conditions. Vaccination status should also be reviewed prior to initiating therapy, as certain vaccines may not be recommended أثناء treatment.
Comprehensive prescribing information, including detailed safety guidelines, should be reviewed carefully, and any questions or concerns should be discussed with a healthcare provider.
The FDA approval of STELARA for pediatric Crohn’s disease represents an important step forward in the evolution of treatment for this challenging condition. By offering a novel mechanism of action and extending its use to younger patients, ustekinumab has the potential to reshape the standard of care for children living with moderate-to-severe disease.
As research continues and additional therapies are developed, the goal remains clear: to provide safe, effective, and personalized treatment options that improve outcomes and quality of life for patients of all ages living with Crohn’s disease.
ABOUT THE PHASE3 UNITI JR STUDY (NCT04673357)
UNITI Jr is a Phase 3, multicenter open-label study evaluating the efficacy, safety, and pharmacokinetics of ustekinumab for the treatment of moderately to severely active Crohn’s disease in pediatric patients two years of age and older.
ABOUT PEDIATRIC CROHN’S DISEASE
Crohn’s disease (CD) is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans.5 Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.6
Symptoms of Crohn’s disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Currently, no cure is available for Crohn’s disease.3 Nearly one million people in the U.S. are living with CD; up to 25% of those individuals are pediatric.3 Crohn’s disease can be more severe for the pediatric population compared to adults, further highlighting the need for additional treatment options.3,4
ABOUT STELARA®(ustekinumab)
STELARA®(ustekinumab), a human interleukin (IL)-12 and IL-23 antagonist, is a prescription medicine approved in the United States to treat:
- adults and children 6 years and older with moderate to severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
- adults and children 6 years and older with active psoriatic arthritis.
- adults 18 years and older with moderately to severely active Crohn’s disease.
- pediatric patients 2 years of age and older with moderately to severely active Crohn’s disease.
- adults 18 years and older with moderately to severely active ulcerative colitis.
The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to STELARA®.
Source Link:https://www.jnj.com/
